Key result
Intravenous nicorandil improves myocardial strain and microvascular obstruction before primary PCI without improving major cardiovascular events.
Why the study?
Nicorandil has been proposed as a cardioprotective agent in STEMI, but its effects on myocardial strain and long-term MACE have not been systematically evaluated.
Does intravenous nicorandil pretreatment before primary PCI improve myocardial strain and reduce long-term major adverse cardiovascular events in STEMI patients?
RCT (n=73)
Double-blind
Randomized
No
Does intravenous nicorandil pretreatment before primary PCI improve myocardial strain and reduce long-term major adverse cardiovascular events in STEMI patients?
Intravenous nicorandil pretreatment prior to primary PCI in STEMI patients improves CMR-derived myocardial and left atrial strain and reduces microvascular obstruction and infarct size, though without a significant difference in long-term MACE.
Answers are grounded in this paper and cite their sources.
Nicorandil may confer early myocardial protection in STEMI; leaves open impact on clinical outcomes.
Myocardial strain provides a sensitive and reliable assessment of myocardial function during the acute phase of ST-segment elevation myocardial infarction (STEMI). Nicorandil has been proposed as a cardioprotective agent, but its effects on myocardial strain have not been systematically evaluated. This study aimed to evaluate the effects of nicorandil on myocardial strain and long-term major adverse cardiovascular events (MACE) in STEMI patients. This post hoc, exploratory single-center substudy of the randomized, double-blind, placebo-controlled CLEAN trial included 73 STEMI patients with evaluable CMR data who had been allocated to intravenous nicorandil ( n = 36) or placebo ( n = 37) before primary PCI. Cardiac magnetic resonance (CMR) was performed at a median of 4 (3, 5) days. MACE were recorded over a median follow-up of 42 (36, 46) months. Compared with the control group, the nicorandil group demonstrated significantly improved global longitudinal strain, global circumferential strain, global radial strain, Left atrial (LA) reservoir strain, and LA booster strain ( P < 0.05), while LVEF did not differ significantly ( P = 0.348). Late gadolinium enhancement, microvascular obstruction (MVO) incidence, and caIMR were all significantly lower in the nicorandil group ( P < 0.05). There was no statistically significant difference in MACE-free survival between groups (log-rank P = 0.186). Among STEMI patients with evaluable CMR, intravenous nicorandil pretreatment before primary PCI was associated with more favorable myocardial strain, smaller infarct size, less MVO, and lower caIMR. These exploratory findings require confirmation. ClinicalTrials.gov, NCT04665648; registered on 02 December 2020.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted an RCT in ST-segment elevation myocardial infarction (STEMI) (n=73). Intravenous nicorandil vs. Placebo was evaluated on Myocardial strain (global longitudinal, circumferential, radial, and left atrial reservoir and booster strain) and microvascular obstruction on CMR (p=<0.05). Intravenous nicorandil before primary PCI improved myocardial strain and reduced microvascular obstruction vs placebo, without affecting major cardiovascular events-free survival.
Synapse has enriched 10 related papers. Consider them for comparative context: